homepage-top-section

The combination therapy is intended to treat previously untreated diffuse large B-cell lymphoma (DLBCL), which is the most common form of non-Hodgkin lymphoma (NHL). It is claimed to

The regulatory agency has issued a complete response letter (CRL) to the Biologics License Application (BLA) for sintilimab, which is being co-developed by Innovent Biologics. It recommended the companies

Led by Fidelity Management & Research Company, the financing round has seen participation of new investors that include 3W Partners Capital and Invus, along with existing investors including

Co-led by Leaps by Bayer and Vida Ventures, the round has seen participation from other investors including Catalio Capital Management, The Parker Institute for Cancer Immunotherapy, Erasca Ventures,

An anti-programmed death receptor-1 (PD-1) therapy, Keytruda increases the ability of the immune system in the body for detecting and fighting tumour cells. It works by blocking the

Opdualag is a fixed-dose dual immunotherapy combination treatment of the programmed death-1 (PD-1) inhibitor nivolumab and novel Lymphocyte activation gene-3 (LAG-3)-blocking antibody relatlimab. The drug is indicated to

The financing round has seen participation from existing investors Northpond Ventures, Leaps by Bayer, the impact investment unit of Bayer AG. New investors including the Myeloma Investment Fund,

Under the deal, the companies will develop radiolabelling chemistry and analytical methods which will be utilised in future pre-clinical and clinical studies. Actinium-225 (225Ac) is an alpha particle-emitting

Under the collaboration, funds managed by Blackstone Life Sciences (BXLS) will provide $329.1m (€300m) to speed up the pivotal studies as well as clinical development programme for a